CDDO-Me redirects activation of breast tumor associated macrophages

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Ball, Michael S ^a   Shipman, Emilie P ^a   Kim, Hyunjung ^a   Liby, Karen T ^a   Pioli, Patricia A ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BARDOXOLONE METHYL; CD163 ANTIGEN; CD206 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; LYMPHOCYTE ANTIGEN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; CYTOKINE; METHYL 2-CYANO-3,12-DIOXOOLEAN-1,9-DIEN-28-OATE; OLEANOLIC ACID; TUMOR MARKER;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PROTEIN ANALYSIS; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; BREAST TUMOR; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MACROPHAGE; METABOLISM; PATHOLOGY; SECRETION (PROCESS);

ANIMALS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL PROLIFERATION; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; OLEANOLIC ACID; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 84960441088     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149600     Document Type: Article

References (67)

1. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breastcancer incidence in 2003 in the United States. N Engl J Med. 2007; 356(16):1670-4. Epub 2007/04/20. doi: 356/16/1670 [pii] doi: 10.1056/NEJMsr070105 PMID: 17442911.
2. Jatoi I, Chen BE, Anderson WF, Rosenberg PS. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol. 2007; 25(13):1683-90. Epub 2007/04/04. doi: JCO.2006.09.2106 [pii] doi: 10.1200/JCO.2006.09.2106 PMID: 17404367.
3. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4(1):71-8. Epub 2004/01/07. doi: 10.1038/nrc1256 nrc1256 [pii]. PMID: 14708027.
4. Espey MG. Tumor macrophage redox and effector mechanisms associated with hypoxia. Free Radic Biol Med. 2006; 41(11):1621-8. Epub 2006/12/06. doi: S0891-5849(06)00548-X [pii] doi: 10.1016/j. freeradbiomed.2006.08.026 PMID: 17145549; PubMed Central PMCID: PMC1934898.
5. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002; 196(3):254-65. Epub 2002/02/22. doi: 10. 1002/path.1027 [pii] 10.1002/path.1027. PMID: 11857487.
6. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001; 193(6):727-40. Epub 2001/03/21. PMID: 11257139; PubMed Central PMCID: PMC2193412.
7. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol. 2003; 163(5):2113-26. Epub 2003/10/28. doi: S0002-9440(10)63568-7 [pii] doi: 10.1016/S0002-9440(10)63568-7 PMID: 14578209; PubMed Central PMCID: PMC1892434.
8. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454 (7203):436-44. doi: 10.1038/nature07205 PMID: 18650914.
9. Mantovani A, Sica A, Allavena P, Garlanda C, Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Human immunology. 2009; 70(5):325-30. doi: 10.1016/j.humimm.2009.02.008 PMID: 19236898.
10. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. The Journal of clinical investigation. 2012; 122(3):787-95. doi: 10.1172/JCI59643 PMID: 22378047; PubMed Central PMCID: PMC3287223.
11. Klimp AH, de Vries EG, Scherphof GL, Daemen T. A potential role of macrophage activation in the treatment of cancer. Critical reviews in oncology/hematology. 2002; 44(2):143-61. PMID: 12413632.
12. Liby KT, Sporn MB. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacological reviews. 2012; 64(4):972-1003. doi: 10.1124/pr.111.004846 PMID: 22966038; PubMed Central PMCID: PMC3462991.
13. Tran K, Risingsong R, Royce D, Williams CR, Sporn MB, Liby K. The synthetic triterpenoid CDDOmethyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice. Cancer prevention research. 2012; 5(5):726-34. doi: 10.1158/1940-6207.CAPR-11-0404 PMID: 22401982.
14. Mentzer SJ, Guyre PM, Burakoff SJ, Faller DV. Spontaneous aggregation as a mechanism for human monocyte purification. Cell Immunol. 1986; 101(2):312-9. Epub 1986/09/01. PMID: 3757046.
15. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science. 2010; 327(5966):656-61. Epub 2010/02/06. doi: 10.1126/science.1178331 327/5966/656 [pii]. PMID: 20133564; PubMed Central PMCID: PMC2887389.
16. Zudaire E, Gambardella L, Kurcz C, Vermeren S. A computational tool for quantitative analysis of vascular networks. PloS one. 2011; 6(11):e27385. Epub 2011/11/24. doi: 10.1371/journal.pone.0027385 PMID: 22110636; PubMed Central PMCID: PMC3217985.
17. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014; 41 (1):49-61. doi: 10.1016/j.immuni.2014.06.010 PMID: 25035953; PubMed Central PMCID: PMC4137410.
18. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. European journal of cancer. 2006; 42(6):717-27. doi: 10.1016/j.ejca.2006.01.003 PMID: 16520032.
19. Sica A, Saccani A, Bottazzi B. Autocrine production of IL-10 mediates defective IL-12 production and NF-?B activation in tumor-associated macrophages. The Journal of. 2000. doi: 10.4049/jimmunol. 164.2.762
20. Solinas G, Germano G, Mantovani A. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. Journal of leukocyte. 2009.
21. Gordon S. Alternative activation of macrophages. Nature reviews Immunology. 2002; 3(1):23-35. doi: 10.1038/nri978
22. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009; 9(4):239-52. doi: 10.1038/nrc2618 PMID: 19279573; PubMed Central PMCID: PMC3251309.
23. Solinas G, Schiarea S, Liguori M, Fabbri M, Pesce S, Zammataro L, et al. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. Journal of immunology. 2010; 185(1):642-52. doi: 10.4049/jimmunol.1000413 PMID: 20530259.
24. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nature immunology. 2011; 12(3):231-8. doi: 10.1038/ni.1990 PMID: 21240265.
25. Weiss M, Blazek K, Byrne AJ, Perocheau DP. IRF5 is a specific marker of inflammatory macrophages in vivo. Mediators of. 2013.
26. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends in immunology. 2004; 25(12):677-86. doi: 10. 1016/j.it.2004.09.015 PMID: 15530839
27. Chen J, Yao Y, Gong C, Yu F, Su S, Chen J, et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell. 2011; 19(4):541-55. doi: 10.1016/j.ccr. 2011.02.006 PMID: 21481794
28. M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis. The American journal of pathology. 2011; 178(3):1279-86. doi: 10.1016/j.ajpath.2010.11.065 PMID: 21356378
29. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in immunology. 2002; 23(11). doi: 10.1016/s1471-4906(02)02302-5
30. Shabo I, Stål O, Olsson H, Doré S. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. International Journal of. 2008. doi: 10.1002/ijc.23527
31. Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. Cancer Cell. 2014; 25(6). doi: 10.1016/j.ccr.2014.05.016
32. Holden JA, Attard TJ, Laughton KM, Mansell A, O'Brien-Simpson NM, Reynolds EC. Porphyromonas gingivalis lipopolysaccharide weakly activates M1 and M2 polarized mouse macrophages but induces inflammatory cytokines. Infection and immunity. 2014; 82(10):4190-203. doi: 10.1128/IAI.02325-14 PMID: 25047849; PubMed Central PMCID: PMC4187848.
33. Schmittel A, Scheibenbogen C, Keilholz U. Lipopolysaccharide effectively up-regulates B7-1 (CD80) expression and costimulatory function of human monocytes. Scandinavian journal of immunology. 1995; 42(6):701-4. PMID: 8552995.
34. Lin EY, Jones JG, Li P, Zhu L, Whitney KD. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. The American journal of. 2003.
35. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010; 32(5):593-604. doi: 10.1016/j.immuni.2010.05.007 PMID: 20510870.
36. Darwich L, Coma G, Pena R, Bellido R, Blanco EJ, Este JA, et al. Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. Immunology. 2009; 126(3):386-93. doi: 10.1111/j.1365-2567.2008.02905.x PMID: 18759749; PubMed Central PMCID: PMC2669819.
37. Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood. 2007.
38. Chen WC, Lai YH, Chen HY, Guo HR, Su IJ. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. 2013. doi: 10.1111/his.12156 PMID: 23738752
39. He Z, Zhang H, Yang C, Zhou Y, Zhou Y, Han G, et al. The interaction between different types of activated RAW 264.7 cells and macrophage inflammatory protein-1 alpha. Radiation oncology (London, England). 2010; 6:86. doi: 10.1186/1748-717x-6-86
40. Tripathi C, Tewari BN, Kanchan RK, Baghel KS, Nautiyal N, Shrivastava R, et al. Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin. Oncotarget. 2014; 5(14):5350-68. PMID: 25051364
41. Scotton C, Milliken D, Wilson J, Raju S, Balkwill F. Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours. British journal of cancer. 2001; 85(6):891-7. doi: 10.1054/bjoc. 2001.2020 PMID: 11556842; PubMed Central PMCID: PMC2375063.
42. Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer letters. 2008. doi: 10.1016/j.canlet.2008.03.018
43. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer metastasis reviews. 2006; 25(3):357-71. doi: 10.1007/s10555-006-9003-5 PMID: 17016763
44. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S. Macrophage infiltration and its prognostic implications in breast cancer: The relationship with VEGF expression and microvessel density. Oncology Reports. 2005; 14(2):425-31. PMID: 16012726
45. Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ, et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16(6):1812-23. doi: 10.1158/1078-0432.CCR-09-3272 PMID: 20215551; PubMed Central PMCID: PMC2840181.
46. Fujita Y, Okamoto M, Goda H, Tano T, Nakashiro K, Sugita A, et al. Prognostic significance of interleukin-8 and CD163-positive cell-infiltration in tumor tissues in patients with oral squamous cell carcinoma. PloS one. 2014; 9(12):e110378. doi: 10.1371/journal.pone.0110378 PMID: 25461761; PubMed Central PMCID: PMC4251830.
47. Shabo I, Stal O, Olsson H, Dore S, Svanvik J. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. International journal of cancer Journal international du cancer. 2008; 123(4):780-6. doi: 10.1002/ijc.23527 PMID: 18506688.
48. Sulahian TH, Hogger P, Wahner AE, Wardwell K, Goulding NJ, Sorg C, et al. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine. 2000; 12(9):1312-21. doi: 10.1006/cyto.2000.0720 PMID: 10975989.
49. Deng B, Wehling-Henricks M, Villalta SA, Wang Y, Tidball JG. IL-10 triggers changes in macrophage phenotype that promote muscle growth and regeneration. Journal of immunology. 2012; 189(7):3669-80. doi: 10.4049/jimmunol.1103180 PMID: 22933625; PubMed Central PMCID: PMC3448810.
50. Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, Dereuddre-Bosquet N, et al. Macrophage activation switching: an asset for the resolution of inflammation. Clinical and experimental immunology. 2005; 142(3):481-9. doi: 10.1111/j.1365-2249.2005.02934.x PMID: 16297160; PubMed Central PMCID: PMC1809537.
51. Ahmad R, Raina D, Meyer C, Kharbanda S, Kufe D. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. The Journal of biological chemistry. 2006; 281 (47):35764-9. doi: 10.1074/jbc.M607160200 PMID: 16998237.
52. Wang Y, Porter WW, Suh N, Honda T, Gribble GW, Leesnitzer LM, et al. A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Molecular endocrinology. 2000; 14(10):1550-6. doi: 10.1210/mend.14.10.0545 PMID: 11043571.
53. Yang C, Hornicek FJ, Wood KB, Schwab JH, Choy E, Mankin H, et al. Blockage of Stat3 with CDDOMe inhibits tumor cell growth in chordoma. Spine. 2010; 35(18):1668-75. doi: 10.1097/BRS. 0b013e3181c2d2b4 PMID: 20386502.
54. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell metabolism. 2007; 6(2):137-43. doi: 10.1016/j.cmet.2007.06.010 PMID: 17681149.
55. Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, Di Liberto D, et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(35):14978-83. doi: 10. 1073/pnas.0809784106 PMID: 19706447; PubMed Central PMCID: PMC2736429.
56. Qin H, Yeh WI, De Sarno P, Holdbrooks AT, Liu Y, Muldowney MT, et al. Signal transducer and activator of transcription-3/suppressor of cytokine signaling-3 (STAT3/SOCS3) axis in myeloid cells regulates neuroinflammation. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(13):5004-9. doi: 10.1073/pnas.1117218109 PMID: 22411837; PubMed Central PMCID: PMC3323949.
57. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature immunology. 2010; 11(10):889-96. doi: 10.1038/ni.1937 PMID: 20856220
58. Weigert A, Tzieply N, von Knethen A, Johann AM, Schmidt H, Geisslinger G, et al. Tumor cell apoptosis polarizes macrophages role of sphingosine-1-phosphate. Molecular biology of the cell. 2007; 18 (10):3810-9. doi: 10.1091/mbc.E06-12-1096 PMID: 17652460
59. Chen P, Bonaldo P. Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies. Int Rev Cell Mol Biol. 2013; 301:1-35. doi: 10.1016/B978-0-12-407704-1.00001-4 PMID: 23317816.
60. Bynum JA, Rastogi A, Stavchansky SA, Bowman PD. Cytoprotection of human endothelial cells from oxidant stress with CDDO derivatives: network analysis of genes responsible for cytoprotection. Pharmacology. 2015; 95(3-4):181-92. doi: 10.1159/000381188 PMID: 25926128.
61. Vannini N, Lorusso G, Cammarota R, Barberis M, Noonan DM, Sporn MB, et al. The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent. Mol Cancer Ther. 2007; 6(12 Pt 1):3139-46. doi: 10.1158/1535-7163.MCT-07-0451 PMID: 18065492.
62. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008; 8(12):958-69. doi: 10.1038/nri2448 PMID: 19029990; PubMed Central PMCID: PMC2724991.
63. Rego SL, Helms RS, Dreau D. Breast tumor cell TACE-shed MCSF promotes pro-angiogenic macrophages through NF-kappaB signaling. Angiogenesis. 2014; 17(3):573-85. doi: 10.1007/s10456-013-9405-2 PMID: 24197832.
64. Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell. 2014; 26(5):623-37. doi: 10.1016/j.ccell.2014.09.006 PMID: 25446896; PubMed Central PMCID: PMC4254570.
65. Mantovani A, Locati M. Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. Arteriosclerosis, thrombosis, and vascular biology. 2013; 33(7):1478-83. doi: 10.1161/ATVBAHA.113.300168 PMID: 23766387.
66. Meyer T, Stockfleth E. Clinical investigations of Toll-like receptor agonists. Expert opinion on investigational drugs. 2008; 17(7):1051-65. doi: 10.1517/13543784.17.7.1051 PMID: 18549341.
67. Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, et al. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18(12):3396-406. doi: 10.1158/1078-0432.CCR-11-2703 PMID: 22634319.